Covalently Bound Drug Particles on Prosthetic Patches
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prosthetic patches used in vascular surgeries face challenges such as restenosis, neointimal hyperplasia, and anastomotic aneurysm formation due to inadequate drug delivery and systemic toxicity from existing formulations, which require improved localized and sustained delivery of active agents without systemic side effects.
Innovation Solution
Development of composite prosthetic patches with covalently bound particles encapsulating therapeutic agents, such as rapamycin and TGF-β1, using biodegradable polymers like PLGA, which release agents at a controlled rate to prevent neointimal hyperplasia and aneurysm formation, while minimizing systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional prosthetic patch materials (synthetic polymers, pericardiums) are used, then structural integrity and ease of manufacture are improved, but restenosis, neointimal hyperplasia, and thrombosis occur due to lack of localized drug delivery
Solution Approach 1:
The prosthetic patch combines synthetic polymer base material with covalently bound drug-loaded particles (PLGA, chitosan, gelatin) to create a composite structure that provides both mechanical integrity and localized sustained drug delivery capability, preventing restenosis and neointimal hyperplasia
Solution Approach 2:
The patch incorporates drug-loaded particles at specific locations and densities on the patch surface and within its structure, creating localized zones of therapeutic agent delivery that target specific areas prone to restenosis and neointimal hyperplasia without affecting the overall structural properties
2Reliability
If oral administration of rapamycin is used to suppress neointimalhyperplasia, then therapeutic effect is improved, but systemic toxicity occurs including fever, anemia, and capillary leak syndrome
Solution Approach 1:
The system delivers rapamycin locally at the vascular graft site through covalently bound particles on the prosthetic patch, concentrating the therapeutic effect where needed while avoiding systemic circulation and associated toxicities such as fever, anemia, and capillary leak syndrome
Solution Approach 2:
The prosthetic patch with covalently bound particles acts as an intermediary carrier that releases rapamycin locally at the implantation site, mediating between the drug and the target tissue while preventing systemic distribution and associated harmful effects
3Object-affected harmful factors
If slow-release formulations of rapamycin are used, then systemic toxicity is reduced, but restenosis inhibition is inconsistent and insufficient
Solution Approach 1:
The system provides concentrated local delivery of rapamycin at the vascular graft site through covalently bound particles, ensuring sufficient therapeutic concentration for reliable restenosis inhibition while maintaining slow release kinetics to minimize systemic toxicity
Solution Approach 2:
The system changes the delivery parameters by using covalent bonding to achieve sustained release over the critical healing period (days to weeks), optimizing both the release rate and local concentration to reliably prevent restenosis while maintaining low systemic exposure
4Ease of operation
If unbound pharmaceuticals are applied to wet prosthetic patches, then ease of application is improved, but drug detachment occurs during storage and application leading to inconsistent dosing
Solution Approach 1:
The system replaces mechanical/adhesive binding with covalent chemical bonding between the particles and the prosthetic patch, creating a stable, irreversible attachment that prevents drug detachment during storage and application while maintaining ease of use
Solution Approach 2:
The prosthetic patch is formulated as a composite material with covalently bound drug-loaded particles integrated into the polymer matrix, ensuring stable drug retention during storage and application while maintaining the flexibility and ease of handling of the original patch material
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The patches effectively deliver active agents locally, reducing restenosis and aneurysm formation by controlling the release of therapeutic agents, thereby improving vascular health and minimizing adverse effects.
Implementation Method 1
particles encapsulating therapeutic agents, such as rapamycin and TGF-β1, using biodegradable polymers like PLGA, which release agents at a controlled rate
Data Source
AI summary
Composite prosthetic patches with covalently bound particles for controlled drug release, and methods of making and using thereof, have been developed. The particles may encapsulate one or more therapeutic, prophylactic or diagnostic agent(s). Generally, the prosthetic patches are decellularized extracellular matrix such as bovine or porcine pericardium or synthetic polymeric materials. The size of the particles ranges from between 1 nm and 1000 μm, preferably from between 10 nm and 500 nm. In some embodiments, the agent is a therapeutic agent for treatment of neointimal hyperplasia. In other embodiments, the agent is a therapeutic agent for suppressing or resolving inflammation. In yet other embodiments, the agent is a therapeutic for mitigating scarring.